Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
GV20 received an upfront payment and is eligible for additional milestone payments
The fresh capital will propel Cordance into its first-in-human clinical trial
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Subscribe To Our Newsletter & Stay Updated